Latest News About Oppenheimer & Co. Inc.

Here’s the latest on Oppenheimer & Co. Inc. (OPY) based on recent public reporting:

• A notable development involves Oppenheimer’s ongoing activity in earnings and strategic hires. Public updates in 2025 highlighted record earnings for the firm in Q4 and full-year 2025, with growth driven by Wealth Management and Capital Markets, and the firm returning capital to shareholders through a special dividend and buybacks.[1][2]
• The firm also continued expanding its research and sector coverage, including additions to its Biotech/Healthcare research team in late 2025, signaling ongoing focus on healthcare and genetic medicines—part of a broader effort to deepen coverage in growing sectors.[1]
• Earlier in 2025, Oppenheimer expanded its technology and private capital banking capabilities with new hires, reflecting a strategy to bolster capabilities across high-growth areas like technology and biotech.[3][5]
• There have been public disclosures about regulatory-related settlements in prior years (e.g., cash sweep program settlements), with ongoing attention to the firm’s litigation and compliance matters, which occasionally surface in market chatter and regulatory disclosures.[1]

If you’d like, I can:

• Pull the most recent press releases and summarize the key financials and leadership changes in the last 90 days.
• Create a quick snapshot comparing OPY’s recent earnings, AUM trends, and notable hires.
• Set up a watchlist with alert criteria (price, earnings, and press release cadence) and export a concise report.

Would you like a focused update on financial performance, leadership hires, or regulatory/compliance matters? Note: I can also fetch more precise, date-stamped excerpts if you want direct quotes from the latest filings or press releases.